Science News
from research organizations

New target for immuno-oncology therapies

Discovery could have an impact on cancer treatment

Date:
November 16, 2015
Source:
Institut de recherches cliniques de Montreal
Summary:
By studying a type of immune cells, a team of researchers identified the mechanism of action for a new target for novel immune-oncology treatments.
Share:
FULL STORY

By studying a type of immune cells, a team of researchers at the IRCM led by André Veillette, MD, identified the mechanism of action for a new target for novel immune-oncology treatments. Their discovery is published today in the print edition of the scientific journal the Journal of Experimental Medicine.

The researchers study natural killer (NK) cells, which are crucial to the immune system and protect the body by destroying cancer cells. The team is more specifically interested in a protein called DNAM-1 that plays a key role in the elimination of cancer cells.

"We discovered the mechanism by which the DNAM-1 protein stimulates the function of NK cells and, thus, increases their capacity to eliminate cancer cells," says Dr. Veillette, Director of the Molecular Oncology research unit at the IRCM.

The DNAM-1 protein is a receptor located at the surface of NK cells. It competes with other receptors that also want to interact with cancer cells, such as the TIGIT receptor that, on the contrary, reduces the efficiency of NK cells.

"When the TIGIT receptor interacts with an infected cell, it prevents its interaction with the DNAM-1 protein, which, as a result, suppresses the function of NK cells and slows the immune system," explains Dr. Veillette.

Recent discoveries have led to the development of several immuno-oncology treatments (or cancer immunotherapy), which use antibodies to improve the immune system's natural function. Some of these antibodies, namely anti-CTLA-4 or anti-PD-1 antibodies, have already shown lasting benefits for many cancer patients.

"Our results reveal how antibodies against TIGIT could become new therapies in immune-oncology," adds Dr. Veillette. "These antibodies could improve the function of the DNAM-1 protein, thereby improving the ability of NK cells to destroy tumour cells. This type of therapy could have a significant impact on the next generation of cancer treatments."


Story Source:

Materials provided by Institut de recherches cliniques de Montreal. Note: Content may be edited for style and length.


Journal Reference:

  1. Z. Zhang, N. Wu, Y. Lu, D. Davidson, M. Colonna, A. Veillette. DNAM-1 controls NK cell activation via an ITT-like motif. Journal of Experimental Medicine, 2015; 212 (12): 2165 DOI: 10.1084/jem.20150792

Cite This Page:

Institut de recherches cliniques de Montreal. "New target for immuno-oncology therapies: Discovery could have an impact on cancer treatment." ScienceDaily. ScienceDaily, 16 November 2015. <www.sciencedaily.com/releases/2015/11/151116181340.htm>.
Institut de recherches cliniques de Montreal. (2015, November 16). New target for immuno-oncology therapies: Discovery could have an impact on cancer treatment. ScienceDaily. Retrieved May 23, 2017 from www.sciencedaily.com/releases/2015/11/151116181340.htm
Institut de recherches cliniques de Montreal. "New target for immuno-oncology therapies: Discovery could have an impact on cancer treatment." ScienceDaily. www.sciencedaily.com/releases/2015/11/151116181340.htm (accessed May 23, 2017).

RELATED STORIES